echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Prototype of checkpoint response in tumor immunotherapy

    Prototype of checkpoint response in tumor immunotherapy

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    preface

    Currently, the responsiveness of cancer patients to immune checkpoint blockade (ICB) therapy is predicted by different individual measurements with varying degrees of accuracy, including tumor mutation burden, tumor invasive T cell density, dendritic cell frequency, and checkpoint ligand expression


    These are the "seeds" of anti-tumor immunity and are supported


    Immune prototype: multiple associated states of functional targets

    In living tissue and the immune system, cellular states support


    Reactive immune prototypes are collections of cell types that can mediate tumor regression, and the number of cells that make up the reactive immune prototype is sparse and can coexist in tumors that are mainly composed of dominant prototypes


    The figure above provides an overview of how a particular cancer type has different tendencies to support a particular response prototype


    Class I: PROTOTYPE OF CD8-BASED ICB reactions

    CD8+ T cells are characterized by their cell lysis function, which is mediated by interactions between TCR and peptide-MHC I complex (pMHC


    Evidence from mouse models of tumor and chronic viral infection suggests that some CD8+ T cell subsets have different depletion states and have the potential to reactivate effector function


    How are these CD8+TILs activated? The ability of TME cDC1 in mouse tumors to express a large number of stimulating cytokines IL-12 and maintain intake in a neutral pH environment cross-present tumor antigens on MHC I was also essential for amplifying infiltrated


    Finally, a third cell type, Natural Killer (NK) cells, is a key component of


    Class II: PROTOTYPE OF CD4-BASED ICB REACTIONS

    The direct role


    The potential partner of CD4+ T cells in the immune environment of class II reactive tumors is usually cDC2, and in one study, CD11b+cDC2 purified from TME of tumor-bearing mice induced CD4+ T cell expansion and proliferation


    Upregulate the pathways of reaction prototypes

    What other features of these prototypes remain to be revealed? Here are some other intrinsic and extrinsic factors that may facilitate prototypes of Class I and/or Class II reactions


    Reverse T cell depletion

    As mentioned earlier, tumor-specific TRM cells and reversing "depleted" T cells can enhance immune archetype reactivity


    Presents with genetic modifications

    Epigenetics can stabilize TEX cells and prevent cell regeneration, so it may be a determinant


    Regulates endoplasmic reticulum stress

    Activation of endoplasmic reticulum stress and the unfolded protein response (UPR) contributes to the development and progression


    Mast cells

    Mast cells (MCs) have a wide range of receptors and symbiostimulatory molecules to respond quickly to afferent signals and secrete various storage and newly synthesized mediators


    Microbiome

    Mouse studies have shown an association
    between gut bacterial taxa and the ICB response.
    In one study, a healthy human fecal microbiota (FMT) was transplanted into germ-free mice, resulting in CD8+IFN-γ+T cell expansion and enhanced ICB-mediated anti-tumor immunity
    relative to the control group.
    In another study, patients with non-small cell lung cancer had an increased responsiveness to CD4 + Th1 in the blood in the presence of mucophilic Ackermania; When comparing ICB-reactive and non-reactive patients, this correlates with improvement in clinical outcomes
    .
    These results suggest that during ICB treatment, the microbiota can influence key components of class I and ii reactive immune archetypes
    .

    brief summary

    There is substantial evidence that there are at least two "types" of ICB reactivity — Class I and II reactive immune prototypes, whose components already have a well-defined prognosis, and the combination of these traits helps to better predict the reactivity of ICBs
    .
    A more comprehensive understanding of reactive prototypes also has the potential to adapt preclinical screening platforms, or combine with other approaches to improve tumor cure rates
    .

    : ,
    。 Video Applet Like, double tap to cancel Like in Watch, tap twice to cancel Watch

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.